GE Medical Systems and Genometrix Combine Molecular Imaging and Applied Genomics to Advance Disease Diagnosis

WAUKESHA, Wis. and THE WOODLANDS, Texas, April 23

Apr 23, 2001, 01:00 ET from Genometrix Incorporated and GE Medical Systems

/PRNewswire Interactive News Release/ -- GE Medical Systems and Genometrix
 Incorporated have created an alliance to combine genetic and protein data with
 diagnostic imaging to enhance early diagnosis and treatment of cancer and
 other diseases.
     "This agreement will combine the strengths of genomics, functional
 genomics and molecular imaging to put better information in the hands of
 healthcare professionals," said Joseph M. Hogan, president and CEO of GE
 Medical Systems.
     Currently, early detection and treatment of disease is based upon clinical
 chemistry methods combined with family history, lifestyle risk factors and
 diagnostic imaging.  GE Medical Systems and Genometrix have entered into a
 joint research agreement to enable physicians to genetically determine a
 patient's risk for developing disease long before any symptoms appear and
 without unnecessary exploratory procedures to determine that risk.
     GE Medical Systems' non-invasive molecular imaging methods, such as
 positron emission tomography (PET) combined with computed tomography (CT) or
 magnetic resonance imaging (MRI) combined with novel imaging agents, are being
 developed to detect pre-symptomatic disease.  Concurrently, Genometrix's
 genetic- and protein-based analysis systems are being developed to aid in
 defining and identifying patient populations at high risk for specific
 diseases.  GE Medical Systems and Genometrix are combining their molecular
 imaging and applied genomics research to detect and quantify risk levels for
 diseases such as breast and prostate cancer.  The University of Texas M. D.
 Anderson Cancer Center in Houston, Texas, will pilot the initial multi-
 disciplinary research using these combined technologies.
     "Linking imaging information with genetic and protein data will help
 cancer professionals diagnose disease earlier, individualize treatment and
 confirm the effectiveness of treatment," said Dr. Waun Ki Hong, head of the
 Division of Cancer Medicine at M. D. Anderson.
     "We are entering an era where genetic and molecular analysis of disease
 cannot and should not be separated from advances in diagnostic imaging," says
 Mike Hogan, chief scientific officer of Genometrix.  "This alliance offers the
 potential to enhance medical professionals' ability to detect early disease
 and to more accurately distinguish it from other conditions."
 
     About Genometrix Incorporated
     Genometrix Incorporated provides applied genomics technologies and
 knowledge to the healthcare industry.  Genometrix believes that applied
 genomics-the practical use of genetic research and information-is the key to
 reducing the risks, costs and lead-times of drug discovery, predicting disease
 risk, and facilitating the development of personalized medicine.  Genometrix's
 microarray technologies, genomics expertise, archiving and bioinformatics
 services will help to advance the frontier of personalized medicine by
 combining highly innovative technology with efficient operations.  Additional
 information about Genometrix can be obtained at http://www.genometrix.com.
 
     About GE Medical Systems
     GE Medical Systems is a $7 billion global leader in medical information
 and technology.  Its offerings include networking and productivity tools,
 healthcare information systems, patient monitoring systems, conventional and
 digital X-ray, computed tomography (CT), magnetic resonance (MR), ultrasound,
 positron emission tomography (PET), and nuclear medicine.  For more than
 100 years, health care providers worldwide have relied on GE Medical Systems
 for high-quality medical technology, services and productivity solutions.  For
 more information, visit the GE Medical Systems Web site at
 http://www.gemedicalsystems.com.
     Except for the historical information contained herein, the matters set
 forth in this press release are forward-looking statements within the meaning
 of the "safe harbor" provisions of the Private Securities Litigation Reform
 Act of 1995.  These forward-looking statements are subject to risks and
 uncertainties that may cause actual results to differ materially.  Genometrix
 and GE Medical Systems caution that there can be no assurance that actual
 results or conditions will not differ materially from those projected or
 suggested in such forward-looking statements based on a variety of factors,
 including, but not limited to, the companies' early stages of development,
 product developments risks, uncertainty of additional funding, competition,
 reliance on a few customers, and the companies' abilities to protect their
 patents and proprietary rights and commercialize their products.  Genometrix
 and GE Medical Systems disclaim any intent or obligation to update these
 forward-looking statements.
 
      Contact:
      GE Medical Systems
      Patrick Jarvis
      Manager, Media Relations
      262-544-3668
      patrick.jarvis@med.ge.com
 
      Genometrix Inc.
      Roberta M. Ireland
      Senior Manager, Marketing Communications
      281-465-5020
      bireland@genometrix.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X27438777
 
 

SOURCE Genometrix Incorporated and GE Medical Systems
/PRNewswire Interactive News Release/ -- GE Medical Systems and Genometrix
 Incorporated have created an alliance to combine genetic and protein data with
 diagnostic imaging to enhance early diagnosis and treatment of cancer and
 other diseases.
     "This agreement will combine the strengths of genomics, functional
 genomics and molecular imaging to put better information in the hands of
 healthcare professionals," said Joseph M. Hogan, president and CEO of GE
 Medical Systems.
     Currently, early detection and treatment of disease is based upon clinical
 chemistry methods combined with family history, lifestyle risk factors and
 diagnostic imaging.  GE Medical Systems and Genometrix have entered into a
 joint research agreement to enable physicians to genetically determine a
 patient's risk for developing disease long before any symptoms appear and
 without unnecessary exploratory procedures to determine that risk.
     GE Medical Systems' non-invasive molecular imaging methods, such as
 positron emission tomography (PET) combined with computed tomography (CT) or
 magnetic resonance imaging (MRI) combined with novel imaging agents, are being
 developed to detect pre-symptomatic disease.  Concurrently, Genometrix's
 genetic- and protein-based analysis systems are being developed to aid in
 defining and identifying patient populations at high risk for specific
 diseases.  GE Medical Systems and Genometrix are combining their molecular
 imaging and applied genomics research to detect and quantify risk levels for
 diseases such as breast and prostate cancer.  The University of Texas M. D.
 Anderson Cancer Center in Houston, Texas, will pilot the initial multi-
 disciplinary research using these combined technologies.
     "Linking imaging information with genetic and protein data will help
 cancer professionals diagnose disease earlier, individualize treatment and
 confirm the effectiveness of treatment," said Dr. Waun Ki Hong, head of the
 Division of Cancer Medicine at M. D. Anderson.
     "We are entering an era where genetic and molecular analysis of disease
 cannot and should not be separated from advances in diagnostic imaging," says
 Mike Hogan, chief scientific officer of Genometrix.  "This alliance offers the
 potential to enhance medical professionals' ability to detect early disease
 and to more accurately distinguish it from other conditions."
 
     About Genometrix Incorporated
     Genometrix Incorporated provides applied genomics technologies and
 knowledge to the healthcare industry.  Genometrix believes that applied
 genomics-the practical use of genetic research and information-is the key to
 reducing the risks, costs and lead-times of drug discovery, predicting disease
 risk, and facilitating the development of personalized medicine.  Genometrix's
 microarray technologies, genomics expertise, archiving and bioinformatics
 services will help to advance the frontier of personalized medicine by
 combining highly innovative technology with efficient operations.  Additional
 information about Genometrix can be obtained at http://www.genometrix.com.
 
     About GE Medical Systems
     GE Medical Systems is a $7 billion global leader in medical information
 and technology.  Its offerings include networking and productivity tools,
 healthcare information systems, patient monitoring systems, conventional and
 digital X-ray, computed tomography (CT), magnetic resonance (MR), ultrasound,
 positron emission tomography (PET), and nuclear medicine.  For more than
 100 years, health care providers worldwide have relied on GE Medical Systems
 for high-quality medical technology, services and productivity solutions.  For
 more information, visit the GE Medical Systems Web site at
 http://www.gemedicalsystems.com.
     Except for the historical information contained herein, the matters set
 forth in this press release are forward-looking statements within the meaning
 of the "safe harbor" provisions of the Private Securities Litigation Reform
 Act of 1995.  These forward-looking statements are subject to risks and
 uncertainties that may cause actual results to differ materially.  Genometrix
 and GE Medical Systems caution that there can be no assurance that actual
 results or conditions will not differ materially from those projected or
 suggested in such forward-looking statements based on a variety of factors,
 including, but not limited to, the companies' early stages of development,
 product developments risks, uncertainty of additional funding, competition,
 reliance on a few customers, and the companies' abilities to protect their
 patents and proprietary rights and commercialize their products.  Genometrix
 and GE Medical Systems disclaim any intent or obligation to update these
 forward-looking statements.
 
      Contact:
      GE Medical Systems
      Patrick Jarvis
      Manager, Media Relations
      262-544-3668
      patrick.jarvis@med.ge.com
 
      Genometrix Inc.
      Roberta M. Ireland
      Senior Manager, Marketing Communications
      281-465-5020
      bireland@genometrix.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X27438777
 
 SOURCE  Genometrix Incorporated and GE Medical Systems